Trial Profile

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efzofitimod (Primary)
Indications COVID-19 pneumonia
Focus Adverse reactions
Sponsors aTyr Pharma

Most Recent Events

15 Mar 2021 Biomarker results from this phase 2 double-blind, placebo-controlled clinical trial published in the aTyr Pharma Media Release
04 Jan 2021 Status changed from active, no longer recruiting to completed, according to an aTyr Pharma media release.
04 Jan 2021 According to an aTyr Pharma media release, trial met the primary safety endpoint.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com